208 related articles for article (PubMed ID: 8519415)
21. Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer.
Heidenreich B; Heidenreich A; Sesterhenn A; Srivastava S; Moul JW; Sesterhenn IA
Eur Urol; 2000 Oct; 38(4):475-82. PubMed ID: 11025389
[TBL] [Abstract][Full Text] [Related]
22. Alterations of CDKN2 (p16) in non-small cell lung cancer.
de Vos S; Miller CW; Takeuchi S; Gombart AF; Cho SK; Koeffler HP
Genes Chromosomes Cancer; 1995 Nov; 14(3):164-70. PubMed ID: 8589032
[TBL] [Abstract][Full Text] [Related]
23. Primary malignant lymphoma of the brain: demonstration of frequent p16 and p15 gene deletions.
Kumanishi T; Zhang S; Ichikawa T; Endo S; Washiyama K
Jpn J Cancer Res; 1996 Jul; 87(7):691-5. PubMed ID: 8698617
[TBL] [Abstract][Full Text] [Related]
24. Homozygous deletions of p16/MTS1 and p15/MTS2 genes are frequent in t(1;19)-negative but not in t(1;19)-positive B precursor acute lymphoblastic leukemia in childhood.
Ohnishi H; Hanada R; Horibe K; Hongo T; Kawamura M; Naritaka S; Bessho F; Yanagisawa M; Nobori T; Yamamori S; Hayashi Y
Leukemia; 1996 Jul; 10(7):1104-10. PubMed ID: 8683987
[TBL] [Abstract][Full Text] [Related]
25. Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas.
Bisogna M; Calvano JE; Ho GH; Orlow I; Cordón-Cardó C; Borgen PI; Van Zee KJ
Cancer Genet Cytogenet; 2001 Mar; 125(2):131-8. PubMed ID: 11369056
[TBL] [Abstract][Full Text] [Related]
26. Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas.
Tenan M; Benedetti S; Finocchiaro G
Biochem Biophys Res Commun; 1995 Dec; 217(1):195-202. PubMed ID: 8526910
[TBL] [Abstract][Full Text] [Related]
27. Infrequent mutations and no methylation of CDKN2A (P16/MTS1) and CDKN2B (p15/MTS2) in hepatocellular carcinoma in Taiwan.
Lin YW; Chen CH; Huang GT; Lee PH; Wang JT; Chen DS; Lu FJ; Sheu JC
Eur J Cancer; 1998 Oct; 34(11):1789-95. PubMed ID: 9893670
[TBL] [Abstract][Full Text] [Related]
28. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma.
Xiao S; Li D; Corson JM; Vijg J; Fletcher JA
Cancer Res; 1995 Jul; 55(14):2968-71. PubMed ID: 7606711
[TBL] [Abstract][Full Text] [Related]
29. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors.
Naumann M; Savitskaia N; Eilert C; Schramm A; Kalthoff H; Schmiegel W
Gastroenterology; 1996 Apr; 110(4):1215-24. PubMed ID: 8613012
[TBL] [Abstract][Full Text] [Related]
30. Molecular analysis of INK4 genes in breast carcinomas.
Spirin K; Simpson J; Miller C; Koeffler H
Int J Oncol; 1997 Oct; 11(4):737-44. PubMed ID: 21528268
[TBL] [Abstract][Full Text] [Related]
31. Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors.
Zariwala M; Liu E; Xiong Y
Oncogene; 1996 Jan; 12(2):451-5. PubMed ID: 8570224
[TBL] [Abstract][Full Text] [Related]
32. Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma.
Siebert R; Willers CP; Opalka B
Leuk Lymphoma; 1996 Nov; 23(5-6):505-20. PubMed ID: 9031081
[TBL] [Abstract][Full Text] [Related]
33. Tumor suppressor INK4: comparisons of conformational properties between p16(INK4A) and p18(INK4C).
Yuan C; Li J; Selby TL; Byeon IJ; Tsai MD
J Mol Biol; 1999 Nov; 294(1):201-11. PubMed ID: 10556039
[TBL] [Abstract][Full Text] [Related]
34. Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma.
Koduru PR; Zariwala M; Soni M; Gong JZ; Xiong Y; Broome JD
Blood; 1995 Oct; 86(8):2900-5. PubMed ID: 7579381
[TBL] [Abstract][Full Text] [Related]
35. Alterations of p16INK4A and p15INK4B genes in gastric carcinomas.
Lee YY; Kang SH; Seo JY; Jung CW; Lee KU; Choe KJ; Kim BK; Kim NK; Koeffler HP; Bang YJ
Cancer; 1997 Nov; 80(10):1889-96. PubMed ID: 9366289
[TBL] [Abstract][Full Text] [Related]
36. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.
Packenham JP; Taylor JA; White CM; Anna CH; Barrett JC; Devereux TR
Clin Cancer Res; 1995 Jul; 1(7):687-90. PubMed ID: 9816033
[TBL] [Abstract][Full Text] [Related]
37. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors.
Ichikawa Y; Yoshida S; Koyama Y; Hirai M; Ishikawa T; Nishida M; Tsunoda H; Kubo T; Miwa M; Uchida K
Int J Cancer; 1996 Dec; 69(6):466-70. PubMed ID: 8980248
[TBL] [Abstract][Full Text] [Related]
38. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies.
Ogawa S; Hangaishi A; Miyawaki S; Hirosawa S; Miura Y; Takeyama K; Kamada N; Ohtake S; Uike N; Shimazaki C
Blood; 1995 Aug; 86(4):1548-56. PubMed ID: 7632963
[TBL] [Abstract][Full Text] [Related]
39. Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15(INK4b) methylation status.
Chaussade L; Eymin B; Brambilla E; Gazzeri S
Oncogene; 2001 Oct; 20(45):6587-96. PubMed ID: 11641784
[TBL] [Abstract][Full Text] [Related]
40. The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance.
Diccianni MB; Chau LS; Batova A; Vu TQ; Yu AL
Cancer Lett; 1996 Jul; 104(2):183-92. PubMed ID: 8665486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
